Gyre Therapeutics, Inc.
- GYRE
- NASDAQ
- Biotechnology
- Anti-fibrotic Drugs
- Inflammation/Fibrosis
$6.09
Today +0.16%Quote Oct 19, 2026, 08:00 PM UTC
−19.34%over the last month
Max drawdown −19.5%From 1-month high −19.3%3 months +0.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Gyre Therapeutics
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
625
Market value
$645.7M
Quote Oct 19
Floor
$5.72
6.0% below price
Resistance
$6.40
5.0% above price
Price vs analyst targets
1 analyst
Lowest target
$16.00Highest target
$18.00
$16.00Highest target
$18.00
- Price $6.09
- Average target $17.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 179% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GYREPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free